<bill session="117" type="s" number="889" updated="2023-01-11T13:47:37Z">
  <state datetime="2021-03-22">REFERRED</state>
  <status>
    <introduced datetime="2021-03-22"/>
  </status>
  <introduced datetime="2021-03-22"/>
  <titles>
    <title type="display">Prescription Drug Monitoring Act of 2021</title>
    <title type="official" as="introduced">A bill to require the use of prescription drug monitoring programs.</title>
    <title type="short" as="introduced">Prescription Drug Monitoring Act of 2021</title>
  </titles>
  <sponsor bioguide_id="K000367"/>
  <cosponsors>
    <cosponsor bioguide_id="K000383" joined="2021-03-22"/>
    <cosponsor bioguide_id="M001183" joined="2021-03-22"/>
    <cosponsor bioguide_id="P000449" joined="2021-03-22"/>
  </cosponsors>
  <actions>
    <action datetime="2021-03-22">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-03-22" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="4341" relation="unknown"/>
    <bill session="117" type="s" number="987" relation="unknown"/>
    <bill session="117" type="h" number="2344" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Criminal justice information and records"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Health information and medical records"/>
    <term name="Health personnel"/>
    <term name="Intergovernmental relations"/>
    <term name="Licensing and registrations"/>
    <term name="Medical ethics"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2021-06-01T14:54:46Z" status="Introduced in Senate">Prescription Drug Monitoring Act of 2021

This bill imposes, as a condition on certain federal funding for the Prescription Drug Monitoring Program (PDMP), additional notification and reporting requirements concerning prescriptions for potentially addictive drugs.

States or territories that receive this funding must require

 prescribers to consult the PDMP before starting treatment with such drugs, and dispensers to report within 24 hours to the PDMP each time they fill a prescription for such drugs. In addition, the state agency administering a PDMP must analyze reported data for patterns of prescription drug misuse or abuse and provide certain information to prescribers, law enforcement, the public, and other states and territories.</summary>
</bill>
